Table 2: BMI Comparison: Drug User
Cohort to NJBRFS and NHIS data. (N = 151).
|
BMI Classification |
||||||||||||
|
Underweight |
Normal Weight |
Overweight |
Obese |
|||||||||
Category |
Cohort |
NJBRFS |
NHIS |
Cohort |
NJBRFS |
NHIS |
Cohort |
NJBRFS |
NHIS |
Cohort |
NJBRFS |
NHIS |
|
|
Obs (% of
151) |
Obs/Exp |
Obs/Exp |
Obs (% of
151) |
Obs/Exp |
Obs/Exp |
Obs (%
of 151 |
Obs/Exp |
Obs/Exp |
Obs (% of
151) |
Obs/Exp |
Obs/Exp |
|
|
|
|
|
|
|
|
|
|
|
||||
Overall |
7 (4.6) |
3.52** |
3.98** |
40 (26.5) |
0.93 |
1.00 |
40 (26.5) |
0.70* |
0.79 |
64 (42.4) |
1.30* |
1.01 |
|
Hispanic |
1 (0.7) |
2.58 |
5.52 |
7 (4.6) |
0.84 |
0.91 |
9 (6.0) |
0.61 |
0.66 |
17 (11.3) |
1.62 |
1.37 |
|
Black NH |
4 (2.6) |
6.71** |
7.36** |
14 (9.3) |
1.20 |
1.17 |
14 (9.3) |
0.63 |
0.73 |
27 (17.9) |
1.11 |
0.99 |
|
White NH |
2 (1.3) |
2.34 |
2.21 |
19 (12.6) |
0.87 |
1.00 |
15 (9.9) |
0.80 |
0.87 |
19 (12.6) |
1.40 |
1.06 |
|
Male |
3 (2.0) |
7.44** |
7.69* |
16 (10.6) |
1.22 |
1.13 |
22 (14.6) |
0.76 |
0.84 |
21 (13.9) |
1.08 |
0.99 |
|
Female |
4 (2.65) |
2.52 |
2.92 |
24 (15.9) |
0.81 |
0.92 |
18 (11.9) |
0.65 |
0.73 |
43 (28.5) |
1.44* |
1.16 |
|
21-35 |
1 (0.7) |
1.83 |
1.91 |
9 (6.0) |
0.84 |
0.95 |
4 (2.6) |
0.59 |
0.63 |
9 (6.0) |
1.81 |
1.35 |
|
36-40 |
1 (0.7) |
5.26 |
6.65 |
4 (2.6) |
0.80 |
0.85 |
5 (3.3) |
0.66 |
0.72 |
8 (5.3) |
1.54 |
1.28 |
|
41-45 |
1 (0.7) |
9.26 |
7.78 |
4 (2.6) |
1.04 |
1.18 |
2 (1.3) |
0.46 |
0.50 |
5 (3.3) |
1.36 |
1.12 |
|
46-50 |
N.C. |
N.C. |
N.C. |
2 (1.3) |
0.40 |
0.47 |
5 (3.3) |
0.64 |
0.70 |
14 (9.3) |
1.76 |
1.48 |
|
51-55 |
1 (0.7) |
3.57 |
5.20 |
8 (5.3) |
1.25 |
1.37 |
6 (4.0) |
0.62 |
0.70 |
11 (7.3) |
1.14 |
0.97 |
|
56-60 |
1 (0.7) |
2.53 |
4.06 |
7 (4.6) |
1.16 |
1.23 |
7 (4.6) |
0.70 |
0.80 |
11 (7.3) |
1.16 |
0.97 |
|
61-65 |
N.C. |
N.C. |
N.C. |
4 (2.6) |
1.01 |
0.92 |
7 (4.6) |
1.04 |
1.24 |
5 (3.3) |
0.99 |
0.87 |
|
66-85 |
N.C. |
N.C. |
13.91* |
2 (1.3) |
1.03 |
0.83 |
N.C. |
N.C. |
1.16 |
1 (0.7) |
0.31 |
0.33 |
|
Younger Group (Subjects ≤50) |
3 (2.0) |
3.01 |
3.18 |
18 (11.9) |
0.74 |
0.87 |
16 (10.6) |
0.61* |
0.66 |
36 (23.8) |
1.68** |
1.34 |
|
Older Group (Subjects >50) |
4 (2.6) |
4.03** |
4.89* |
22 (14.6) |
1.18 |
1.15 |
24 (15.9) |
0.79 |
0.91 |
28 (18.5) |
1.01 |
0.89 |
|
PWID |
5 (3.3) |
4.15* |
4.37* |
23 (15.2) |
0.75 |
0.94 |
25 (16.6) |
0.81 |
0.91 |
29 (19.2) |
1.22 |
1.01 |
|
Non-PWID |
17 (11.2) |
2.55 |
3.27 |
15 (9.9) |
1.02 |
1.09 |
35 (23.2) |
0.58* |
0.65 |
4 (2.6) |
1.38 |
1.19 |
|
Note: Standardized Prevalence Ratios were calculated
to examine differences between drug user cohort, NJBRFS, and NHIS data.
Boldface indicates statistical significance in two-tailed Fisher exact test (*
p < 0.05 and ** p < 0.01).
PWID: Persons who inject drugs.
N.C.:
Non-Calculable due to absence of data in the reference database, which excluded
data when those databases had small numbers of persons in the cells; NH:
Non-Hispanic.